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Abstract 
Loss of the tumor suppressor tuberous sclerosis complex 1 (Tsc1) in the liver promotes 
gluconeogenesis and glucose intolerance.  We asked whether this could be attributed to 
aberrant expression of small RNAs.  We performed small-RNA sequencing on liver of Tsc1 
knock-out mice, and found that miRNAs of the delta like homolog 1 (Dlk1) – deiodinase 
iodothyronine type III (Dio3) locus are upregulated in an mTORC1-dependent manner.  
Sustained mTORC1 signaling during development prevented CpG methylation and silencing 
of the Dlk1-Dio3 locus, thereby increasing miRNA transcription.  Deletion of miRNAs 
encoded by the Dlk1-Dio3 locus reduced gluconeogenesis, glucose intolerance and fasting 
blood glucose levels. Thus, miRNAs contribute to the metabolic effects observed upon loss 
of TSC1 and hyperactivation of mTORC1 in the liver.  Furthermore, we show that miRNA is a 
downstream effector of hyperactive mTORC1 signaling. 
 
 
 
 
 
Significance 
Organisms maintain a constant level of blood glucose.  mTOR, an atypical serine/threonine 
kinase, plays a major role in glucose metabolism.  This is evident in mouse models where 
disruption of mTOR signaling can cause a phenotype similar to a pre-diabetic state.  
However, how mTOR signaling affects blood glucose levels is incompletely understood.  
Here we show that sustained activation of mTORC1 enhances expression of miRNAs of the 
Dlk1-Dio3 cluster to induce gluconeogenesis and increase blood glucose levels.  Enhanced 
miRNA expression correlates to a reduction in levels of DNA methylation at the Dlk1-Dio3 
locus. Our findings reveal a connection between miRNAs, mTOR signaling and glucose 
metabolism, and may provide a new strategy in the treatment of metabolic disease. 
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Introduction 
Mammalian Target of Rapamycin (mTOR) signaling integrates inputs from growth factors, 
nutrients and intracellular cues to regulate cell growth and metabolism (1, 2). mTOR forms 
two structurally and functionally distinct complexes, mTOR complex 1 (mTORC1) and 
mTORC2 (3, 4). Dysregulation of either complex can lead to metabolic disease and cancer (5, 
6). A major negative regulator of mTORC1 is the tumor suppressor TSC complex that is 
composed of tuberous sclerosis 1 (TSC1), TSC2 and TBC1 domain family member 7 (TBC1D7) 
(7). Disruption of the TSC complex leads to increased mTORC1 signaling and disease (8, 9). 
There are a number of mouse models with aberrant mTOR signaling, virtually all of which 
exhibit dysregulation of glucose metabolism (10). Models in which mTOR signaling is 
upregulated develop tumors (10). For example, upregulation of mTORC1 signaling in mouse 
liver, achieved by deleting Tsc1, leads to impaired glucose homeostasis within weeks and to 
liver cancer within approximately 12 months (11-13). 
The known effectors downstream of the mTOR complexes are proteins. Little is 
known about non-coding RNAs (ncRNAs), in particular microRNAs (miRNAs), that may 
mediate downstream effects of mTOR. miRNAs are a class of short non-coding RNAs 
involved in many aspects of cell growth and metabolism and, like mTOR, affect glucose 
metabolism and tumorigenesis (14). For example, dysregulation of a single miRNA, miR-122, 
in the liver affects liver metabolism and causes tumorigenesis (15, 16). miR-122 and other 
miRNAs are involved in liver development and homeostasis, and also in liver disease (17). 
Any given miRNA represses many targets and, as such, alterations in expression of one or a 
small number of miRNAs can impact many downstream processes (18). The coordinated 
control of many targets by a single miRNA is a means to mediate complex processes such as 
cellular metabolism. 
miRNAs are encoded throughout the genome, including at imprinted loci from which 
expression is regulated by CpG methylation and heterochromatin maintenance in an allele-
specific manner (19). The largest imprinted miRNA cluster is part of the Dlk1-Dio3 locus, 
found in mouse chromosome 12. This is a nearly 1Mb imprinted locus that carries three 
paternally expressed protein-coding genes (Dlk1, retrotransposon-like protein 1 (Rtl1) and 
Dio3), and several maternally expressed non-coding genes. The latter include long non-
coding RNA (lncRNA) genes, such as maternally expressed 3 (Meg3), Anti-Rtl1, RNA 
imprinted and accumulated in nucleus (Rian) and miRNA containing gene (Mirg), small 
nucleolar RNA (snoRNA) genes, Piwi-interacting RNA (piRNA) genes and more than 50 
miRNA genes (20, 21). Like all imprinted loci, expression at the Dlk1-Dio3 locus is controlled 
by CpG methylation of so-called imprinting control regions (ICRs). ICRs determine whether 
the paternal or maternal allele is expressed (21). The Dlk1-Dio3 locus miRNAs, expressed 
from the maternal chromosome, are studied mainly in brain and placenta and are reported 
to be involved in metabolic disease and tumorigenesis (20, 22, 23). 
It is well documented that miRNAs affect proteins involved in mTOR signaling (24, 
25). However, only a few reports describe mTOR-mediated regulation of miRNA expression 
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(26-28). Moreover, to our knowledge, there is no evidence that mTOR signaling can affect 
specific miRNAs to control cellular metabolism. To determine whether miRNAs play a role in 
the metabolic alterations seen upon dysregulation of mTOR signaling, we examined miRNA 
expression in liver-specific Tsc1 knock-out mice, hereafter referred as L-Tsc1KO mice. We 
report that upon loss of Tsc1, aberrantly constitutive mTORC1 signaling upregulates 
expression of miRNAs of the imprinted Dlk1-Dio3 locus to enhance gluconeogenesis. These 
findings reveal a novel mode of mTORC1 signaling, showing that mTORC1 engages miRNAs 
to regulate metabolism. 
 
Results 
Non-coding RNAs of the Dlk1-Dio3 locus are up-regulated in L-Tsc1KO mouse liver. We 
utilized the L-Tsc1KO mouse model to investigate how miRNAs may contribute to the 
metabolic phenotypes observed upon constitutively high mTORC1 activity (SI Appendix, Fig. 
S1A). We performed small-RNA sequencing on livers of L-Tsc1KO animals and littermate 
controls, at 14 weeks of age when L-Tsc1KO mice display disrupted glucose metabolism but 
no sign of tumorigenesis. We found 31 and 6 miRNAs upregulated and downregulated, 
respectively, in L-Tsc1KO mice compared to controls (Fig. 1A, SI Appendix, Table S1). qPCR 
confirmed the changes in expression in all cases examined (Fig. 1B). 26 of the 31 
upregulated miRNAs are encoded by the Dlk1-Dio3 locus (SI Appendix, Table S1, miRNAs in 
bold). 
DNA methylation at three distinct CpG regions, DLK1 differentially methylated region 
(DLK1-DMR), intergenic differentially methylated region (IG-DMR) and MEG differentially 
methylated region (MEG-DMR) controls expression of genes at the Dlk1-Dio3 locus (29-31) 
(SI Appendix, Fig. S1B). The non-coding genes of the locus are expressed, from the maternal 
chromosome, as one transcript (21, 32, 33). Consistent with a single transcript, the Meg3, 
Rian and Mirg long non-coding RNAs were upregulated in L-Tsc1KO mice (Fig. 1C). Four 
other Dlk1-Dio3 locus transcripts expressed from the maternal chromosome, the small 
nucleolar RNA MBII-343, the non-coding transcript ICR-ncRNA, and two pre-miRNAs were 
also upregulated (34) (Fig. 1D). In contrast, expression of the Dlk1 and Dio3 protein-coding 
genes did not change (Fig. 1C and SI Appendix, Fig. S1C). Thus, transcription of non-coding 
genes from the Dlk1-Dio3 locus is up-regulated in the liver of L-Tsc1KO mice.  
 
Up-regulation of Dlk1-Dio3 locus miRNAs is mTORC1 dependent. The miRNAs of the Dlk1-
Dio3 locus are expressed in pluripotent stem cells and in brain and placenta in adult mice 
(35). Furthermore, they are expressed in all tissues during embryogenesis and repressed 
after birth in liver and other tissues (36, 37). In contrast, we detected sustained expression 
of the miRNAs in L-Tsc1KO liver at 14 weeks of age. To determine whether the miRNAs are 
up-regulated throughout postnatal development, we measured hepatic expression of 3 
Dlk1-Dio3 miRNAs, at 2, 4 and 8 weeks of age. Mature miRNA levels were similar in control 
and L-Tsc1KO mice up to 4 weeks of age (SI Appendix, Fig. S2A). However, at 8 weeks, the 
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miRNAs were significantly more abundant in L-Tsc1KO mice (SI Appendix, Fig. S2A). This was 
due primarily to loss of miRNA expression in control littermates at 8 weeks, i.e., aberrantly 
sustained expression in the L-Tsc1KO mice (Fig. 2A). The L-Tsc1KO livers even exhibited a 
small increase in miRNA levels at 8 weeks compared to 4 weeks. (Fig. 2A). We further 
observed a clear downregulation of the three miRNAs at 8 weeks in pure C57BL/6J (wild 
type) mice compared to 4-week-old mice (Fig. 2B). These results demonstrate a 
physiological downregulation of Dlk1-Dio3 locus miRNAs at 4 to 8 weeks of age. 
Furthermore, loss of Tsc1 prevents this downregulation. 
To determine if high mTORC1 activity in L-Tsc1KO mice is responsible for the 
observed dysregulation of Dlk1-Dio3 locus miRNAs, we treated control and L-Tsc1KO mice 
with rapamycin, an allosteric mTORC1 inhibitor, or INK128, an mTOR kinase site inhibitor, 
from 4 to 8 weeks of age. Long term rapamycin and INK128 treatment partly reduced 
expression of the miRNAs at 8 weeks in L-Tsc1KO mice (Fig. 2C and D, SI Appendix Fig. S2B 
and C). INK128 also had a mild inhibitory effect on the already low levels of Dlk1-Dio3 locus 
miRNAs in control mice at 8 weeks (Fig. 2D). Also, we note that mTOR signaling was not 
altered in untreated control mice at 4 and 8 weeks of age (SI Appendix, Fig. S2D). Thus, 
although the physiological inhibition of the Dlk1-Dio3 locus miRNAs in wild type mice 
appears to be independent of mTOR signaling, elevated mTORC1 activity in L-Tsc1KO mice 
maintains hepatic expression of Dlk1-Dio3 locus miRNA beyond 4 weeks of age. 
To determine if the downregulation of miRNAs from 4 to 8 weeks is transcriptional, 
we assessed the hepatic levels of the lncRNAs of the Dlk1-Dio3 locus at 4 and 8 weeks. 
Levels of Meg3, Rian and Mirg were comparable in 4-week-old control and L-Tsc1KO livers 
but significantly increased in 8-week-old L-Tsc1KO livers compared to controls (SI Appendix, 
Fig. S3A and B). Mirroring the level of miRNAs, the level of the lncRNAs was significantly 
reduced in control animals at 8 weeks when compared to 4-week-old mice. Moreover, 8-
week-old L-Tsc1KO animals displayed a significant increase in levels of Meg3, Rian and Mirg, 
when compared to 4-week-old control or L-Tsc1KO livers (Fig. 2E). Similar to the miRNAs, 
long term rapamycin and INK-128 treatment prevented the high expression of Meg3, Rian 
and Mirg in L-Tsc1KO livers (Fig. 2F and G). Thus, constitutively high mTORC1 signaling 
sustains expression of Dlk1-Dio3 miRNAs and other non-coding RNAs beyond 4 weeks of 
age. 
 
mTOR prevents CpG methylation at the MEG-DMR of the Dlk1-Dio3 locus. CpG methylation 
of the IG and MEG DMRs, that lie between the Dlk1 and Meg3 genes, controls expression of 
the entire Dlk1-Dio3 locus (21, 38). Methylation at the IG-DMR is thought to determine 
imprinting of the locus, while methylation of MEG-DMR appears to play a secondary role in 
controlling expression (39, 40). Bisulfite pyrosequencing revealed that CpG methylation at 
IG-DMR and MEG-DMR was significantly increased in control mice at 8 weeks of age 
compared to 4 weeks (Fig. 3A), which likely explains the reduced expression of miRNAs and 
other ncRNAs of the Dlk1-Dio3 locus. Interestingly, L-Tsc1KO livers at 8 weeks of age showed 
significantly reduced CpG methylation of MEG-DMR but not of IG-DMR, compared to 
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controls (Fig. 3A and SI Appendix, Fig. S3C). Both DMRs exhibited similar CpG methylation 
levels in L-Tsc1KO and control samples at 4 weeks of age (SI Appendix, Fig. S3C). To confirm 
the methylation results obtained by bisulfite pyrosequencing, we assessed methylation 
changes using an assay based on cleavage by the HpaII and MsaI restriction enzymes, 
hereafter referred to as the restriction assay. We measured CpG methylation at sites 
adjacent to IG-DMR and MEG-DMR, as described in materials and methods section. Similar 
to the pyrosequencing results, the restriction assay showed an increase in CpG methylation 
at both DMRs in 8-week-old pure C57BL/6J (wild type) mice as compared to 4-week-old 
animals (Fig. 3B). As before, CpG methylation was reduced only at the MEG-DMR in 8-week-
old L-Tsc1KO mouse livers compared to controls (Fig. 3C and D). 
Next, we used the two methylation assays to determine the CpG methylation status 
of the MEG-DMR upon long term rapamycin or INK-128 treatment. Treatment was started 
at 4 weeks of age and the livers were examined at 8 weeks. The restriction assay revealed 
that rapamycin treated L-Tsc1KO animals showed an increase in CpG methylation at MEG-
DMR as compared to vehicle treated controls (Fig. 3E). INK-128 treatment had a more 
pronounced effect in preventing loss of MEG-DMR methylation in L-Tsc1KO liver compared 
to controls (Fig. 3F and G). The partially increased CpG methylation in drug treated 8-week-
old livers suggests that constitutively high mTORC1 signaling in L-Tsc1KO mice prevents CpG 
methylation of MEG-DMR and thereby sustains miRNA expression. 
As the level of Dlk1-Dio3 locus miRNAs was sustained in L-Tsc1KO animals even at 14 
weeks of age, we assessed the CpG methylation of MEG-DMR at this timepoint. L-Tsc1KO 
mice exhibited reduced CpG methylation at MEG-DMR at 14 weeks of age, as observed at 8 
weeks, compared to controls (Fig. 3H). Thus, the failure to CpG methylate MEG-DMR is also 
observed in older mice.  
Methylation at many imprinted sites, including the Dlk1-Dio3 locus, is maintained by 
the zinc finger protein 57 (ZFP57) – KRAB associated protein 1 (KAP1) – SET domain 
bifurcated 1 (SETDB1) complex. This complex recruits DNA methyl transferases (DNMTs) for 
de novo methylation, maintains already methylated CpG sites, and recruits other chromatin 
remodelers, such as nucleosome remodeling histone deacetylase (NURD) complex and 
heterochromatin protein 1 (HP1), to maintain a repressive chromatin environment (41, 42). 
Chromatin immunoprecipitation revealed decreased occupancy of KAP1 and SETDB1 at 
MEG-DMR in L-Tsc1KO liver (Fig. 3I, SI Appendix Fig. S3D and E). As the ZFP57-KAP1-SETDB1 
complex maintains heterochromatin at CpG sites, we assessed histone occupancy at MEG-
DMR in L-Tsc1KO liver at 14 weeks. We observed a reduction in overall histone occupancy in 
L-Tsc1KO liver, compared to controls (Fig. 3J, SI Appendix Fig. S3F). These findings suggest 
that the reduced presence of the ZFP57-KAP1-SETDB1 complex at MEG-DMR accounts for 
the decreased methylation at the Dlk1-Dio3 locus in L-Tsc1KO liver. 
Taken together, the above experiments support a model where aberrantly sustained 
mTORC1 activity disrupts CpG methylation and heterochromatin silencing of the Dlk1-Dio3 
locus that occurs starting at 4 weeks of age. Lack of both CpG methylation and 
heterochromatin silencing in L-Tsc1KO livers is maintained as mice age and contributes to 
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the continuous expression of the non-coding genes from the Dlk1-Dio3 locus. Our findings 
also suggest that MEG-DMR, rather than IG-DMR, is the main site mediating transcriptional 
repression of non-coding genes. Constitutively high mTORC1 activity prevents CpG 
methylation and heterochromatin silencing at MEG-DMR, resulting in sustained expression 
of miRNAs and the lncRNAs of the Dlk1-Dio3 locus.  
 
Aberrant expression of Dlk1-Dio3 miRNAs causes metabolic defects. L-Tsc1KO mice exhibit 
increased gluconeogenesis and glucose intolerance (10, 43, 44). To determine if this 
phenotype is due to aberrantly high expression of Dlk1-Dio3 miRNAs, we introduced a 
deletion of the so-called miR-379/miR-410 region of the Dlk1-Dio3 locus into the L-Tsc1KO 
mouse (SI Appendix, Fig. S4A). The miR-379/miR-410 region includes 41 miRNA genes of the 
Dlk1-Dio3 locus. We note that this deletion does not change mTORC1 signaling (SI Appendix, 
Fig. S4B). As shown previously, full body deletion of the miR-379/miR-410 region, hereafter 
referred to as miRKO , causes partial (30%) litter mortality upon weaning due to a defect in 
glucose metabolism, in particular low blood glucose (45). Like miRKO mice, L-Tsc1KO miRKO 
mice displayed partial litter mortality and no obvious phenotype as adults. We performed 
glucose tolerance tests (GTT) and pyruvate tolerance tests (PTT) on control, L-Tsc1KO, 
miRKO and L-Tsc1KO miRKO mice. L-Tsc1KO mice exhibited glucose intolerance and 
increased gluconeogenesis, whereas miRKO mice displayed neither, as compared to control 
mice (Fig. 4A and B, SI Appendix Fig. S4C and D). Interestingly, L-Tsc1KO miRKO mice showed 
improved glucose tolerance and reduced gluconeogenesis compared to L-Tsc1KO mice (Fig. 
4C and D). These observations suggest that aberrantly increased levels of the Dlk1-Dio3 
locus miRNAs play a role in the metabolic phenotype of L-Tsc1KO mice. 
Glucose-6-phosphatase (G6P), fructose-1,6-bisphosphatase (FBP), phospho-enol-
pyruvate carboxykinase (PEPCK) and pyruvate carboxylase (PC) are enzymes that catalyze 
gluconeogenesis. The genes expressing these enzymes were upregulated in L-Tsc1KO mice, 
as compared to control mice, and reduced in L-Tsc1KO miRKO mice, as compared to L-
Tsc1KO mice (Fig. 4E and F). Further, rapamycin treatment showed a trend in 
downregulation of expression of the gluconeogenetic genes (SI Appendix Fig. S4E) in a 
manner, as shown above, that correlates with decreased levels of Dlk1-Dio3 locus miRNAs, 
in L-Tsc1KO mice. It was previously shown that the increased rate of gluconeogenesis in L-
Tsc1KO mice, compared to wild type controls, is due to reduced Protein Kinase B (PKB, also 
known as AKT) signaling that in turn leads to de-repression of the Forkhead Box Protein 
(FOXO) transcription factors (11, 44). We did not see a significant difference in 
phosphorylation of AKT and FOXO in L-Tsc1KO liver compared to L-Tsc1KO miRKO liver (SI 
Appendix Fig. S4F). Thus, Dlk1-Dio3 miRNAs promote gluconeogenesis via transcriptional 
activation of gluconeogenic genes and this effect is independent of the AKT-FOXO axis. 
Gluconeogenesis is turned on during periods of fasting to maintain blood glucose 
levels. After 18 hours of fasting, blood glucose levels in L-Tsc1KO mice were high compared 
to controls (Fig. 4G). Interestingly, the increased fasting blood glucose levels were 
normalized in L-Tsc1KO miRKO mice as compared to L-Tsc1KO mice (Fig. 4H). These results 
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suggest that miRNAs of the Dlk1-Dio3 locus, in particular the miRNAs in the miR-379/miR-
410 region, maintain blood glucose levels during fasting. Taken together, our findings 
suggest that pathologically high mTOR signaling induces expression of miRNAs to promote 
gluconeogenesis. Furthermore, we propose that high mTORC1 signaling induces miRNA 
expression most likely by preventing CpG methylation of the Dlk1-Dio3 locus (Fig. 5). 
 
Discussion 
Here we show that constitutively high mTORC1 signaling, due to loss of the tumor 
suppressor Tsc1, up-regulates miRNAs of the Dlk1-Dio3 locus to possibly increase 
gluconeogenesis. Furthermore, we report that the developmentally expressed miRNAs of 
the Dlk1-Dio3 locus are transcriptionally silenced in the liver of wild type mice at 4 to 8 
weeks of age, but remain expressed in L-Tsc1KO livers. Sustained expression of the Dlk1-
Dio3 locus miRNAs, upon high mTOR activity, correlated with lower CpG methylation of the 
Dlk1-Dio3 locus. 
How does pathologically high mTORC1 activity (loss of Tsc1) prevent CpG 
methylation of the Dlk1-Dio3 locus to maintain expression of miRNAs? In wild type mouse 
livers, we observed more CpG methylation at IG-DMR and MEG-DMR of the Dlk1-Dio3 locus 
at 8 weeks of age, compared to 4 weeks. Loss of Tsc1 prevented CpG methylation at MEG-
DMR but not at IG-DMR. The interplay between IG-DMR and MEG-DMR CpG methylation 
and downstream consequences are still being unraveled (29, 46-48), but our data suggest 
that methylation at the IG- and MEG-DMRs  are independently controlled. TSC1 appears to 
promote methylation at MEG-DMR without affecting methylation at IG-DMR. How loss of 
TSC1 prevents CpG methylation at MEG-DMR is unclear. CpG methylation is maintained by 
the ZFP57-KAP1-SETDB1 complex. We observed reduced histone and ZFP57-KAP1-SETDB1 
complex occupancy at MEG-DMR upon loss of TSC1. The reduced binding by the complex 
could lead to decreased recruitment of the histone depositing enzyme HP1 which would in 
turn account for less histones and increased miRNA expression. mTORC1 may 
phosphorylate members of the ZFP57-KAP1-SETDB1 complex, accounting for the increase in 
miRNA expression upon loss of TSC1. Interestingly, KAP1 was detected as a potential mTOR 
substrate in large scale screens (49-51). Alternatively, mTORC1 may phosphorylate a factor 
directly involved in transcription of Dlk1-Dio3 locus miRNAs. Sustained mTOR activity may 
promote recruitment of this factor to MEG-DMR, thereby preventing methylation of the 
site. Proteins such as DPPA3, AFF3 or CTCF have been shown to act at the MEG-DMR (52-
55). It would be interesting to determine if they are targets of mTOR. 
How do the miRNAs of the Dlk1-Dio3 locus activate gluconeogenesis? Upon deletion 
of the miR-379/miR-410 region in L-Tsc1KO mice, we observed reduced transcription of 
gluconeogenic genes. It is possible that Dlk1-Dio3 locus miRNAs promote gluconeogenesis 
by inhibiting one or more negative regulators of gluconeogenic enzymes. AKT negatively 
regulates gluconeogenic genes by phosphorylating and inhibiting FOXO transcription 
factors. Loss of TSC1 reduces, via a negative feedback loop, AKT activity but deletion of the 
miR-379/miR-410 region in the L-Tsc1KO background did not restore phosphorylation of 
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AKT and FOXO. Thus, the effect of Dlk1-Dio3 locus miRNAs on gluconeogenesis appears to 
be independent or downstream of the AKT-FOXO axis. Also, gluconeogenic flux is controlled 
post-transcriptionally via increased levels of AMP and/or changes in the NAD+/NADH ratio 
(56-59). It is possible that increased expression of Dlk1-Dio3 locus miRNAs alters the level of 
AMP and/or NAD+/NADH ratio which may in turn affect gluconeogenesis. It remains to be 
determined how up-regulation or deletion of the Dlk1-Dio3 locus affects gluconeogenesis 
and fasting blood glucose levels. We also note that the miR-379/miR-410 region of the Dlk1-
Dio3 locus is deleted in the entire body and, as such, the phenotype seen with the L-Tsc1KO 
miRKO mice could potentially originate outside of the liver.  
Our findings add a new dimension to mTOR signaling and how it affects glucose 
metabolism. To our knowledge, this is the first report showing that mTORC1 signals through 
miRNA, and does so to impact glucose metabolism. Sustained expression of Dlk1-Dio3 locus 
miRNAs can explain the pathological increase in gluconeogenesis and blood glucose levels 
upon loss of TSC1. Dlk1-Dio3 locus miRNAs may be necessary to maintain elevated glucose 
levels in blood and tissues during mouse embryogenesis and periods of lactation. However, 
in adult mice, aberrantly increased levels of these miRNAs may cause high blood glucose 
levels that can produce a pre-diabetic phenotype. The Dlk1-Dio3 locus found in mouse 
chromosome 12, is conserved in humans in chromosome 14 and is linked to disease upon 
dysregulation. Consistent with our findings, patients with Temple Syndrome, characterized 
with increased expression of Dlk1-Dio3 locus miRNAs, are obese and may develop diabetes 
(60, 61). The targets of Dlk1-Dio3 locus miRNAs and how they affect gluconeogenesis 
remain to be identified.  
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Materials and Methods 
 
RNA isolation 
Total RNA was isolated from 50mg of mouse liver and was homogenized in 1ml TRIzol 
(Sigma) using lysing matrix D tubes (Q-Biogene) and a bead beater. Subsequent steps were 
performed as per TRIzol manufacturer’s instructions. 
 
Small RNA sequencing and analysis 
Total RNA was isolated as described above and 1ug of total RNA was used to generate small 
RNA libraries for sequencing as described in (62). Libraries were sequenced on an Illumina 
HiSeq-2500 deep sequencer. For analysis, the raw miRNA sequencing data was uploaded to 
the ClipZ server (63) for adapter removal and annotation. Differentially expressed miRNAs 
were extracted using DESeq (64) implemented as a Bioconductor package. A cutoff at 0.05 
for the adjusted p-value provided by DESeq was used to filter the hits. 
 
Quantitative Reverse Transcriptase PCR 
For mRNAs quantitative PCR was performed from 200ng of total RNA, isolated as described 
above. DNAse digestion was performed using the Roche RNAse free DNAse kit (Roche) as 
per manufacturer’s instructions. cDNA synthesis was performed using iScript (Bio-RAD) as 
per manufacturer’s instructions. Samples were diluted 10 times prior to usage as a template 
in qPCR reactions together with SYBR Green Mix (Applied Biosystems) and primers. An 
Applied Biosystems StepOnePlus Real-Time PCR System was used. Relative expression levels 
were determined by normalizing each CT value to TBP expression using the DDCT method. 
Sequences of the primers used are in supplemental table 3. 
For miRNAs quantitative PCR was performed from 2pg of total RNA that was used as a 
template together with the Applied Biosystems miRNA kit (Applied Biosystems) as per 
manufacturer’s instructions to generate cDNA. miRNA Taqman primers from Invitrogen for 
miR-127, miR-34a, miR-376b, miR-381, miR-455, miR-541 and miR-802 (Cat #4427975) were 
used to perform the PCR reaction together with Taqman Universal 2X mastermix (Applied 
Biosystems) as per manufacturer’s instructions. An Applied Biosystems StepOnePlus Real-
Time PCR Systems was used. Relative expression levels were determined by normalizing 
each CT value to U6 expression using the DDCT method. Sequences of other primers used 
are shown in supplemental table 3. 
 
Protein isolation and western blotting 
Livers from mice were rapidly dissected and flash frozen in liquid nitrogen. For protein 
extraction liver tissues were homogenized using Polytron machine (Polytron) in ice-cold T-
PER lysis buffer (Invitrogen) supplemented with protease and phosphatase inhibitors 
(Sigma). Lysates were cleared by centrifugation at 10,000xg for 15 minutes at 40C. Total 
protein concentration was assessed using a BCA Protein Assay kit (Invitrogen) as per 
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manufacturer’s instructions. 10ug of protein was loaded on a gradient SDS/PAGE gel and 
transferred to a nitrocellulose membrane for blotting. Antibodies used are shown in 
supplemental table 2. Samples were probed overnight with primary antibody and 1 hour 
with secondary antibody conjugated to HRP. Supersignal West Pico chemiluminescent kit 
(Thermo Fischer) was used to detect staining in a Fusion X machine (Vilber). 
 
Rapamycin and INK128 treatments 
For chronic mTOR inhibition 4-week-old mice were injected intraperitoneally daily for 4 
weeks with Rapamycin at 1mg/kg or INK128 at 0.5mg/kg or the respective vehicle. 
Rapamycin was dissolved in 5% PEG-400, 4% Ethanol and 5% Tween 80. INK128 was 
dissolved in 5% 1-methyl-2-pyrrolidinone, 15% polyvinylpyrrolidone K30 and 80% water. In 
all cases the injection volume did not supersede 100ul. 
 
Statistical analysis 
Unless stated otherwise, statistical significance was measured using a Student’s unpaired t 
test to determine differences among groups. The differences were considered to be 
significant if p < 0.05.  Data are presented as mean ± SEM. The asterisks represent the 
degree of significance: * p<0.05; ** p<0.01, *** p<0.001. 
 
Glucose, and Pyruvate Tolerance Tests 
For glucose tolerance tests (GTT) mice were fasted for 18 hours and administered 2g/kg of 
body weight glucose by intraperitoneal injection (i.p.). Blood glucose levels were measured 
in 10-minute intervals for 180 minutes. For pyruvate tolerance tests (PTT) mice were fasted 
for 18 hours before administering 2g/kg of body weight sodium pyruvate via i.p. injection. 
Blood glucose levels were measured in 10-minute intervals for a duration of 150 minutes. 
For each test at least 6 male mice of 14 to 16 weeks of age per condition were used.  
 
Mouse Husbandry 
L-Tsc1KO mice and miRKO mice were generated as described previously (45, 50). L-Tsc1KO 
miRKO mice were generated during this work by crossing L-Tsc1KO mice to miRKO mice. 
Littermate controls were used in all experiments. To determine the genotype PCR was done 
as described previously (45, 65). Mice were maintained under temperature and humidity-
controlled conditions with 12-hour light and 12-hour dark cycle with free access to food and 
water. All experiments were performed in accordance with federal guidelines and were 
approved by the Kantonales Veterinaeramt of Kanton Basel-Stadt. 
 
Pyrosequencing analysis 
Tissues were ground in dry ice and DNA was isolated using DNA blood and tissue kit 
(Qiagen) as per manufacturer’s instructions. Five-hundred nanograms of high-purity, intact 
DNA was used for bisulfite conversion using an EZ DNA Methylation-Gold kit (Zymo 
Research) by following standard protocols. Bisulfite converted (BSC) DNA quality and 
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concentration was determined using an RNA Pico 6000 Kit on a Bioanalyzer 2100 instrument 
(Agilent Technologies, USA) and Nanodrop 2000 (ThermoScientific). Bisulfite-converted 
(BSC) samples were normalized to 10 ng/µl. Primers were designed according to 
recommendations of (66): IG-DMR_5prime FW-5’-GTGGTTTGTTATGGGTAAGTTT-3’ and RV-
5’(Btn)- CCCTTCCCTCACTCCAAAAATTA-3’; MEG-DMR_5prime FW-5’-
AGTTTGGGATTTAAAATTAAGGTTT-3’ and RV-5’(Btn)-CTAAAAACTATCACCCCCACAT-3’ 
(Microsynth). Promoter fragments were amplified using an AmplyTaq Gold Kit from Applied 
Biosystems (Life Technologies). PCR was done in 30 µl reactions containing the following: 1x 
PCR buffer II, 300 µM deoxynucleotide triphosphates, final 3.5 mM MgCl2, 200 µM of each 
primer, 20 ng of BSC DNA. We used the following cycling conditions: 95°C, 15 min–50 x 
(95°C, 30 s; 55°C, 30 s; 72°C, 30 s)–72°C, 10 min. PCR products were purified and sequenced 
using a PyroMark ID System (Biotage) following the manufacturer’s suggested protocol and 
sequencing primers: for IG-DMR_5prime 5’- GTTTTATGGTTTATTGTATATAATG-3’; for MEG-
DMR_5prime 5’- TTTTTGTTTTAATAATGTTAAATTT-3’ (Microsynth). Controlling for PCR 
temperature bias was done with a series of calibrator samples of known methylation levels. 
Briefly, unmethylated standards were prepared by using two rounds of linear whole-
genome amplification with an Ovation WGA System Kit (Nugene), starting from 10 ng of 
DNA, as recommended by the manufacturer. Methylated standards were made using CpG 
methyltransferase assay with M.SssI (New England Biolabs, USA) starting from 2 µg of 
purified DNA, following the standard protocol. Bisulfite conversion of standard samples was 
done as described above. All samples were analyzed in quadruplicates. Differential 
methylation analysis was performed using linear models, limma R package, multiple linear 
regression was used to determine significance (67). DNA methylation levels were averaged 
across CpGs in the examined promoter regions. To account for multiple testing, we applied 
Bonferroni correction. 
 
Restriction Assay 
DNA from tissues was isolated using DNA blood and tissue kit (Qiagen) as per 
manufacturer’s instructions. Restriction Assays were performed using the EpiJet 5-mC 
analysis kit (Thermo Scientific) as per manufacturer’s instructions. The following primers 
were used to check for the methyl-C at the IG-DMR and MEG-DMR. For IG-DMR 5’- 
CTGCAGCCGCTATGCTATG-3’ and 5’- CAGCTAACCTGAGCTCCATG-3’. For MEG-DMR 5’- 
GACGAAGAGCTGGAATAGAG-3’ and 5’-CATGTCCAGGAGGACGGAG-3’ 
 
Measuring Fasting Blood Glucose Levels 
In order to measure the fasting blood glucose levels mice were starved for 18 hours a 
minimal amount of tail skin was cut and an Aviva glucometer device (Accu-check) was used 
to measure the concentration of glucose in a drop of blood. For each test at least 6 male 
mice of 14 to 16 weeks of age were used.  
 
Chromatin Immunoprecipitation 
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Mouse livers were homogenized in cold PBS solution and crosslinked with 1% formaldehyde 
for 15 min at room temperature. Crosslinking was stopped with 0.125M glycine and 
homogenates were centrifuged at 600xg for 15 minutes. The cell pellets were resuspended 
in lysis buffer (5mM Pipes, 85mM KCl, 0.5% Nonidet P-40) supplemented with protease 
inhibitors (Roche) and incubated at room temperature for 30 min. Cell lysates were 
centrifuged at 5000xg for 15 minutes and nuclei were resuspended in nuclei lysis buffer 
(50mM Tris-HCl, 10mM EDTA, 1% SDS) for 30 minutes in room temperature. Chromatin was 
sonicated three times for 15 seconds using a Branson probe sonicator at 80% power setting. 
50ug of DNA was incubated with 1ug of antibody in the cold room overnight and further 
incubated with a mix of A/G beads (Pierce) for 2 hours. Beads were washed three times in 
the cold room as per manufacturer’s instruction and eluted with 0.1M NaHCO3, 1% SDS 
buffer. Crosslinking was reversed by incubation at 650C for 6 hours. DNA was purified using 
phenol chloroform-isoamyl alcohol (25:24:1) extraction and ethanol precipitated. Recovered 
DNA was used in qPCR reactions and data is expressed as percentage of the input. 
Antibodies used are shown in supplemental table 2 and primers used to amplify the DNA 
are 5’- GACGAAGAGCTGGAATAGAG-3’ and 5’- CATGTCCAGGAGGACGGAG-3’ for MEG-DMR, 
for the transcribed region primers that map at GAPDH, (Active Motif 71016) , were used, 
and for the non-transcribed region primers that map to a gene desert (Active Motif 71011) , 
were used.  
 
Data Availability 
Small-RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) 
database, https://www.ncbi.nlm.nih.gov/geo, (accession no. will be provided during proofs). 
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Figure Legends: 
 
Fig. 1: Dlk1-Dio3 locus non-coding genes are up-regulated in L-Tsc1KO mouse livers. 
A) miRNA landscape in L-Tsc1KO mice shown as log2 fold change over Control levels. Black 
dots represent miRNAs that are statistically different (adj.p<0.05) between L-Tsc1KO and 
Control mouse livers. 
B) qPCR validation of a few significantly changing miRNAs. U6 snoRNA is used as a control. 
C) Levels of three lncRNAs, Meg3, Rian and Mirg, as well as the protein-coding genes of the 
Dlk1-Dio3 locus measured by qPCR shown as fold change to Control.  
D) Levels of other non-coding genes found at the Dlk1-Dio3 locus, ICR-ncRNA (a non-coding 
transcript associated with increased transcription), snoRNA-MBII-343 and two pre-miRNAs 
(pre-miR-127 and pre-miR-541), shown as fold change over Control. 
 
Fig. 2: Sustained mTOR signaling up-regulates expression of Dlk1-Dio3 locus non-coding 
genes in 8-week-old L-Tsc1KO mice. 
A) qPCR showing miRNA levels of 4 and 8-week-old livers from Control or L-Tsc1KO mice. 
Values are shown as fold change to the control 4-week-old livers.  
B) qPCR showing mature miRNA levels in C57BL/6J (wild type) mice at 4 and 8 weeks of age. 
Values are shown relative to 4-week-old values. 
C) qPCR showing mature miRNA levels upon treatment with vehicle or rapamycin (Rapa 
bars). Values are shown as fold change comparisons of L-Tsc1KO (Vehicle treated) and L-
Tsc1KO Rapa (Rapamycin treated) to Control mice (Vehicle treated). To assess significance L-
Tsc1KO values are compared to Control values and L-Tsc1KO Rapa values are compared to L-
Tsc1KO values.  
D) qPCR showing mature miRNA levels upon treatment with vehicle or INK128 (INK128 
bars). Values are shown as fold change comparisons of L-Tsc1KO (Vehicle treated), L-Tsc1KO 
INK128 (INK128 treated) and Control INK128 (INK128 treated) to Control mice (Vehicle 
treated). To assess significance L-Tsc1KO values are compared to Control values and L-
Tsc1KO INK128 values are compared to L-Tsc1KO values.  
E) qPCR showing Meg3, Rian and Mirg levels of 4 and 8-week-old mouse livers from Control 
or L-Tsc1KO mice. Values are shown as fold change to the Control 4-week mouse livers. 
F) qPCR showing Meg3, Rian and Mirg levels upon treatment with vehicle or rapamycin 
(Rapa bars). Values are shown as fold change comparisons of L-Tsc1KO (Vehicle treated) and 
L-Tsc1KO Rapa (Rapamycin treated) to Control mice (Vehicle treated). To assess significance 
L-Tsc1KO values are compared to Control values and L-Tsc1KO Rapa values are compared to 
L-Tsc1KO values.  
G) qPCR showing Meg3, Rian and Mirg levels upon treatment with vehicle or INK128 
(INK128 bars). Values are shown as fold change comparisons of L-Tsc1KO (Vehicle treated), 
L-Tsc1KO INK128 (INK128 treated) and Control INK128 (INK128 treated) to Control mice 
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(Vehicle treated). To assess significance L-Tsc1KO values are compared to Control values and 
L-Tsc1KO INK128 values are compared to L-Tsc1KO values.  
 
Fig 3: CpG methylation and histone occupancy is reduced in L-Tsc1KO livers at 8 weeks of 
age. 
A) CpG methylation, measured via bisulfite pyrosequencing, at IG-DMR and MEG-DMR in 4-
week and 8-week livers of Control and L-Tsc1KO mice. Values are shown as log2 fold change 
over 4-week-old liver samples of the respective genotype. The median and the range in CpG 
methylation is shown for each sample. Nlme R-package is used to determine significance. 
B) Percent methylation measured at IG-DMR and MEG-DMR for 4 and 8-week-old wild type 
mice.  
C) Percent methylation measured at IG-DMR and MEG-DMR for 4-week-old Control and L-
Tsc1KO mice.  
D) Percent methylation measured at IG-DMR and MEG-DMR for 8-week-old Control and L-
Tsc1KO mice.  
E) Percent CpG methylation measured at IG-DMR and MEG-DMR via restriction assay using 
livers from 8-week-old Control and L-Tsc1KO mice that were treated with vehicle or 
Rapamycin (Rapa labeled) for 4 weeks from 4 weeks of age. To assess significance L-Tsc1KO 
values are compared to Control values and L-Tsc1KO Rapa values are compared to L-Tsc1KO 
values. 
F) Percent CpG methylation measured at IG-DMR and MEG-DMR via restriction assay using 
livers from 8-week-old Control and L-Tsc1KO mice that were treated with vehicle or INK128 
(INK128 labeled) for 4 weeks from 4 weeks of age. To assess significance L-Tsc1KO values 
are compared to Control values and L-Tsc1KO INK128 values are compared to L-Tsc1KO 
values.  
G) CpG methylation, measured via bisulfite pyrosequencing, at MEG-DMR in 8-week-old 
Control and L-Tsc1KO mouse livers treated with vehicle or INK128 for 4 weeks starting at 4-
weeks of age. Values are shown as log2 fold change difference of L-Tsc1KO mouse livers, 
either vehicle or INK128 treated, over control mouse livers of the same treatment. The 
median and the range in CpG methylation is shown for each sample. Nlme R-package is used 
to determine significance. 
H) Percent CpG methylation measured at the MEG-DMR using livers from 14-week-old 
Control and L-Tsc1KO mice. 
I) ChIP assay showing occupancy of KAP1 and SETDB1 at MEG-DMR regions of Control and L-
Tsc1KO mice. Data are shown as fold change compared to occupancy of respective Control 
samples. 
J) ChIP assay showing occupancy of H2A, H3 and H4 histone proteins at MEG-DMR regions 
of Control and L-Tsc1KO mice. Data are shown as percent of the input. 
 
Fig 4: Dlk1-Dio3 locus miRNAs play a role in gluconeogenesis and glucose metabolism. 
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In this figure at least 4 male mice of 14 to 16 weeks of age were used per condition. 
A) Glucose Tolerance Test (GTT) of Control and L-Tsc1KO mice. Area under the curve (AUC) 
is shown to right to determine significance. 
B) Pyruvate Tolerance Test (PTT) of Control and L-Tsc1KO mice. Area under the curve (AUC) 
is shown to right to determine significance.  
C) Glucose Tolerance Test (GTT) of L-Tsc1KO versus L-Tsc1KO miRKO mice. Area under the 
curve (AUC) is shown to right of each graph to determine significance. 
D) Pyruvate Tolerance Test (PTT) of L-Tsc1KO versus L-Tsc1KO miRKO mice. Area under the 
curve (AUC) is shown to right to determine significance.  
E) qPCR showing transcript levels of enzymes involved in the gluconeogenesis pathway. The 
comparison between L-Tsc1KO mice to Control mice is shown. 
F) qPCR showing transcript levels of enzymes involved in the gluconeogenesis pathway. The 
comparison between L-Tsc1KO miRKO mice to L-Tsc1KO mice is shown.  
G) Blood glucose levels measured after 18 hours of starvation. The comparison of L-Tsc1KO 
mice to Control mice is shown.  
H) Blood glucose levels measured after 18 hours of starvation. The comparison between L-
Tsc1KO miRKO and L-Tsc1KO mice is shown. 
 
Fig 5: Loss of TSC1 regulates Dlk1-Dio3 locus miRNAs to affect gluconeogenesis. 
Changes with regard to Dlk1-Dio3 locus miRNAs are depicted in 4-week versus 8-week-old 
animals in Control and L-Tsc1KO mice. CpG islands at IG-DMR and MEG DMR are shown with 
filled (methylated) or empty (unmethylated) circles, miRNAs are shown with vertical lines. 
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